Manga Gratiela, Calin George A, Manuc Mircea, Droc Gabriela, Tudor Stefan
Chirurgia (Bucur). 2018 Jul-Aug;113(4):464-468. doi: 10.21614/chirurgia.113.4.464.
Sepsis represents a systemic illness, characterized by life-threatening organ dysfunction induced by infection. Early diagnostic, evaluation of severity of sepsis with aggressive resuscitation and administration of appropriate antibiotics are associated with improved outcomes. In 2016 a new definition of sepsis (Sepsis-3) was proposed. The key element of sepsis-induced organ dysfunction is defined by "an acute change in total SOFA score >= 2 points consequent to infection". The use of SIRS criteria as identification of sepsis was abandoned and subcategory of severe sepsis was eliminated. A wide spectrum of biomarkers had been proposed for potential use in sepsis, more than in other diseases, outlying the complex pathophysiology of this condition. The first study reporting the clinical value of circulating miRNAs in sepsis showed that both leukocytes and plasma miR-150 levels are significantly reduced in sepsis patients compared with controls and correlate with sepsis severity. Several miRNAs were found differentially expressed in sepsis patients, but most of the published studies failed to find miRNA biomarkers that could differentiate sepsis from SIRS. A solution to this problem seems to be building and analyzing miRNA network in sepsis patients.
脓毒症是一种全身性疾病,其特征是由感染引起的危及生命的器官功能障碍。早期诊断、通过积极复苏评估脓毒症的严重程度以及使用适当的抗生素与改善预后相关。2016年提出了脓毒症的新定义(脓毒症-3)。脓毒症诱导的器官功能障碍的关键要素定义为“因感染导致序贯器官衰竭评估(SOFA)总分急性变化≥2分”。不再使用全身炎症反应综合征(SIRS)标准来识别脓毒症,严重脓毒症的子类别也被取消。与其他疾病相比,已经提出了多种生物标志物可能用于脓毒症,这突出了该病症复杂的病理生理学。第一项报道循环微小RNA(miRNA)在脓毒症中临床价值的研究表明,与对照组相比,脓毒症患者的白细胞和血浆miR-150水平均显著降低,且与脓毒症严重程度相关。在脓毒症患者中发现了几种差异表达的miRNA,但大多数已发表的研究未能找到能够区分脓毒症和SIRS的miRNA生物标志物。解决这个问题的一个办法似乎是构建和分析脓毒症患者的miRNA网络。